Morgan Stanley analyst Patrick Wood notes that the FDA recently posted a class 2 notice on the Dv5 system and says that “while the base release was spotted by the buyside, amidst the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback